tbuckley/cabot-search huggingface dataset:
Multigene Sets for Clinical Application in Glioma
Authors: John F. de Groot, Erik P. Sulman, Kenneth D. Aldape
Journal: Journal of the National Comprehensive Cancer Network (2011)

Diffuse gliomas are a heterogeneous group of malignancies with highly variable outcomes, and diagnosis is largely based on histologic appearance. Tumor classification according to cell type and grade provides some prognostic information. However, significant clinical and biologic heterogeneity exists in glioma, even after accounting for known clinicopathologic variables. Significant advances in knowledge of the molecular genetics of brain tumors have occurred in the past decade, largely because of the availability of high-throughput profiling techniques, including new sequencing methodologies and multidimensional profiling by The Cancer Genome Atlas project. The large amount of data generated from these efforts has enabled the identification of prognostic and predictive factors and helped to identify pathways driving tumor growth. Implementing these signatures into the clinic to personalize therapy presents a new challenge. Identification of relevant biomarkers, especially when coupled with clinical trials of newer targeted therapies, will enable better patient stratification and individualization of treatment for patients with glioma.
The relationship between EGFR gene copy number and EGFR mutation and clinical predicting significance in the Chinese patients with advanced non-small cell lung cancer patients.
Authors: L. Zhao, H. Bai, M. Zhuo, J. Zhao, J. Duan, Z. Wang, Y. Wang, M. Wu, T. An, J. Wang
Journal: Journal of Clinical Oncology (2010)

e18082 Background: EGFR mutation and EGFR gene-copy number are two main EGFR-related biomarkers that have been studied in major clinical trials. However, The association of EGFR gene-copy number with mutation and predictive values to EGFR-TKIs treatment in clinically unselected Chinese patients with advanced NSCLC remain to be unclear. We analyze the relationship between EGFR biomarkers status and clinical outcome in the patients received EGFR-TKI therapy. Methods: Total 102 Chinese patients who received EGFR-TKIs therapy were included in this study. Biomarkers included EGFR mutation (DHPLC), EGFR gene-copy number (fluorescence in situ hybridization). Results: Among 102 patients, 32 (31%) had high EGFR gene-copy number. The objective response rate (ORR), disease control rate, progression-free survival (PFS) and median survival time (MST) in the patients with high EGFR gene-copy number were 37.04%,74.07%, 5.13 and 13.20 months, respectively, closed to those with low EGFR gene-copy number (29.33%, 64% 4.75 and 14.70, respectively; p > 0.05). EGFR mutation was detected in 46 out of 102 patients (45%). No relationship was evidenced between EGFR gene-copy number and EGFR mutation (Interaction test p = 0.302). According to EGFR gene-copy number and EGFR mutation status, the patients were divided to four subgroups (FISH+/Mutation-, FISH+/Mutation+, FISH-/Mutation-, FISH-/Mutation+). ORR of four subgroup were 33.33%, 40%, 41% and 20.45%, respectively (p = 0.205). The patients with both EGFR wild-type and low gene-copy number (FISH-/Mutation -) presented poorer ORR than those with EGFR mutation or/and high gene-copy number (20.45% vs 39.66%, p = 0.041). PFS and OS were longer in the patients with co- existing EGFR mutation and high EGFR gene-copy number (7.87 ms, 16.90 ms, respectively) than other three subgroups, but difference didn't reach statistical significance (p = 0.233, p = 0.339). Conclusions: The association was not found between EGFR gene-copy number and mutation in this patient population.The patients with coexisting EGFR mutation and high EGFR gene-copy number had potential better predicting value to EGFR-TKI. No significant financial relationships to disclose.
Evaluation of the sentinel lymph node mapping technique for breast cancer in a community-based teaching hospital
Authors: D. Burbage, E. Penman, D. Dickson Witmer, G. Pahnke, L. Konizer
Journal: Journal of Clinical Oncology (2005)

893 Background: The sentinel lymph node (SLN) procedure has been used with increasing frequency in patients diagnosed with early stage breast cancer. This review evaluated a community based teaching hospital’s experience with the sentinel lymph node biopsy technique. Methods: A retrospective medical record review utilizing the Surgical Registry at a community based teaching hospital and CPT4 codes specific for breast SLN biopsy were analyzed. This was followed by cross-referencing the identified information to the pathology information system and reviewing the final pathology and surgical reports. Results: From July 2002 through September 2003, 19 surgeons performed a total of 219 SLN procedures for breast cancer. Another 4 were attempted, but were unsuccessful in identifying the sentinel lymph node, hence,an axillary lymph node dissection (ALND) was performed. Of the 19 surgeons, 13 (68%) injected Tc99m followed by methylene or isosulfan blue dye. Intraoperatively, a gamma finder was utilized to identify the sentinel node (s). A frozen section was subsequently performed on any identified lymph node as well as for any palpably suspicious lymph node (s). If a sentinel node could not be identified, a level I and II axillary node dissection was performed. The number of SLN procedures performed by each surgeon ranged from one to 48. The mean number of SLN’s excised was 2.3, with a range of one to 7 nodes, with 4 or fewer lymph nodes removed in 90% of the patients. In the 50 patients with a positive SLN, 45 (90%) went on to ALND. In one case, the patient was on a clinical trial and was randomized to receive no further ALND. In the remaining 4 cases, the final pathology revealed 2 cases of micrometastatic disease and 2 cases of macroscopic disease. In 12 patients where an ALND was performed, no further positive nodes were identified. In an additional 6 cases, the SLN was negative on frozen section, but on final pathology, had a positive finding by Immunohistochemical analysis only. Conclusion: Evaluation of the SLN for breast cancer in this community based teaching hospital is similar to results reported in the literature. No significant financial relationships to disclose.
Abstract 18362: Shb Deficient Mice Display an Increased GFR and Augmented Renal Arteriolar Contractions to Adenosine and Ang II
Authors: Xiang Gao, Johan Sällström, Zufu Ma, Michael Welsh, A. Erik. G Persson
Journal: Circulation (2012)

BACKGROUND: Src homology 2 domain-containing protein B ( Shb ) is an adapter protein which regulates several signal transduction cascades and endothelial cell functions. The adenosine-angiotensin II (Ado-Ang II) interaction plays an important role in the regulation of glomerular filtration rate (GFR), vascular resistance and tubuloglomerular feedback. We used Shb -knockout ( Shb -/- ) and wild-type ( Shb +/+ ) mice to investigate their GFR and effectiveness of Ado and Ang II to constrict renal resistance vessels. METHODS: GFR was measured in conscious Shb -/- and Shb +/+ mice using FITC-inulin. Isotonic contractions were measured in isolated and perfused renal afferent arterioles from Shb -/- and Shb +/+ mice. Concentration responses to Ang II (10 -12 to 10 -6 M; 2 minutes each) doses or low-dose Ado (10 -8 mol/l; 15 min) alone, as well as Ado (10 -8 mol/l) in combination with cumulative application of Ang II (10 -12 to 10 -6 mol/l; 2 minutes each) were studied in both genotypes. RESULTS: There was a significantly increased GFR (371 ± 12 µL/min, n=11) in Shb -/- comparing to Shb +/+ (321 ± 11 µL/min, n=8) mice. The maximal arteriolar contraction to Ang II was significantly larger in Shb -/- (87 %; n=8) than in Shb +/+ (54 %; n=8) mice. Low-dose Ado alone contracted afferent arterioles in both genotypes (6% in Shb -/- and 7% in Shb +/+ ). Ado significantly enhanced Ang II constriction in afferent arterioles in both genotypes (to 93% in Shb -/- and to 72 % in Shb +/+ ). CONCLUSION: Low-dose adenosine augments Ang II arteriolar constriction effectiveness, which indicates Ado-Ang II interaction in both Shb -/- and Shb +/+ mice. The absence of Shb increases GFR The underlying mechanisms remain to be resolved.
Non-small cell lung cancer in the new millennium: The effect of FDG-PET on stage distribution
Authors: B. Goodgame, D. Morgensztern, L. Grove, R. Govindan
Journal: Journal of Clinical Oncology (2006)

7205 Background: The stage-wise distribution of NSCLC at the time of initial presentation following the widespread use of positron emission tomography with 2-[ 18 F] fluoro-2-deoxy-D-glucose (FDG-PET) has not been characterized. Frequently quoted estimates of stage distribution are based predominantly on data prior to 2000. FDG-PET was approved in 1998 and has been widely utilized since 2000. We describe here the stage-wise distribution of NSCLC at the time of initial presentation over the past 15 years. Methods: Patients were identified and clinical data were obtained through our institutional tumor registry system. All patients diagnosed with NSCLC between January 1, 1990 and December 31, 2004 were included. All statistical comparisons were performed by X 2 tests. Results: Of 6311 patients identified, 3926 were diagnosed prior to January 1, 2000 and 2385 thereafter. Pathological (surgical) staging was completed in 37% of patients. Given the widespread availability of FDG-PET since 2000, we grouped the analysis by date of diagnosis, before or after January 1, 2000. Before 2000, stage proportions were: I-29%; II-9%; III-31%; IV-30%; and unknown-1%. After January 1, 2000, stage proportions were: I-26%; II-9%; III-26%; IV-37%; and unknown-2%. The percentage of stage IV disease peaked at 40% in 2004. The difference in rates of stage IV disease before and after January 1, 2000 was highly significant (p &lt; 0.0001). Conclusions: We have documented a significant change in the distribution of stages of non-small cell lung cancer in the last five years. The increase in stage IV disease and decreases in stages I &amp; III disease coincide with the widespread adoption of FDG-PET, suggesting an earlier diagnosis of metastatic disease. [Table: see text]
Transcutaneous carbon dioxide monitoring in patients with acute respiratory failure
Authors: Lurdes Planas, Yolanda Ruiz, Nuria Gonzalez, Ana Cordoba, Eva Farrero, Jordi Dorca, Enric Prats
Journal: European Respiratory Journal (2014)

Transcutaneous carbon dioxide (PtcCO2) monitoring is a non-invasive method increasingly being used to assess acute respiratory failure (ARF).However there are conflicting findings when evaluating high levels of PaCO2.  The aim of our study is to evaluate the accuracy of this method in ARF patients according to the severity of hypercapnia.  Method: prospective study including patients with ARF admitted in a RICU, who required arterial blood gas (ABG) analysis. Simultaneously, PtcCO2 was measured (SenTec digital monitor). Data: patients demographics, diagnosis, ABG and PtcCO2. Data are presented as mean ± SD. Relations between PaCO2 and PtcCO2 were assessed by Pearson correlation coefficient and the intraclass correlation coefficient (ICC). Bland-Altman analysis was used to test data dispersion. ANOVA test was used for comparing the difference of PaCO2 and PtcCO2, in different levels of PaCO2: level 1  60 mmHg.  Results: 74 patients, mean age 66 ± 11 years. Most frequent diagnosis was AECOPD (40%). Mean PaCO2 was 58 ± 11 and mean PtcCO2 was 54 ± 10 mmHg. Correlations between PaCO2 and PtcCO2 was r =0,92 (p  Conclusions: our study showed good agreement of PtcCO2 monitoring with ABG. However, we have to take into account two aspects: PtcCO2 undervalues PaCO2 levels and PtcCO2 is less reliable in patients with sever hypercapnia.
Contrasts in Survival of Black and White Cancer Patients, 1960–73
Authors: Lillian M. Axtell, Max H. Myers
Journal: JNCI Journal of the National Cancer Institute (1978)

The summary data contrasting survival of black and white cancer patients whose disease was diagnosed during 1960–66 and 1967–73, presented for 18 forms of cancer, were derived from case material assembled by the Cancer Surveillance, Epidemiology and End Results (SEER) Program, sponsored by the National Cancer Institute. The average black patient was younger than the average white patient during both periods. About 30% of the cancers in black patients were diagnosed as localized neoplasms, compared to 40% of the cancers in whites. With few exceptions, survival for black patients with each form of cancer has continued to be less favorable than for white patients. It was generally closer to that for white patients when the disease was localized, but whites generally still had higher survival rates. In both races, survival for females was better than for males. The greatest differential in survival between the two races was for cancer of the bladder and cancer of the uterine corpus. Multiple myeloma was one type of cancer for which survival for black patients was more favorable than for white patients during 1967–73. For both races, survival rates improved slightly between 1960–66 and 1967–73. Lung cancer was the leading cancer site for both black and white men for both periods; the proportion increased from 18 to 21% for whites and from 20 to 24% for blacks. Among both black and white patients, the greatest improvement in survival between 1960–66 and 1967–73 occurred for patients with Hodgkin's disease. Improvements were also notable for black patients with cancer of the prostate gland, uterine corpus, and stomach and for those with multiple myeloma. Improvements were less dramatic among white patients. The poorer survival results for black patients may have been associated with socioeconomic factors.
Inhibition of Cardiac Myocyte Apoptosis by Zac1, an Essential Transcription Factor for Cardiac Morphogenesis
Authors: Shinsuke Yuasa
Journal: Circulation (2008)

Abstract 475 Shinsuke Yuasa, Takeshi Onizuka, Shimoji Kenichiro, Yohei Ohno, Mie Hara, Toru Egashira, Fumiyuki Hattori, Kageyama Toshimi, Tomofumi Tanaka, Hao Chen, Satoshi Ogawa, Keiichi Fukuda, K...
Use of Liposomal Doxorubicin for Metastatic Breast Cancer Management Across Europe: Results of Eos (European Observatory &amp; Survey)
Authors: V. Lorusso, A. Śmiałowska-Janiszewska, K. Krzemieniecki, S. Antolín Novoa, F. Mefti, J. Janssen, G.G. Steger, B. Bird, M. Turazza, H. Yosef, E. Albuisson, A. Barnadas, G. Batist, J. De Mouzon, F. Erdkamp, R. Leonard, M. Namer, S. Maumus-Robert, M.S. Aapro
Journal: Annals of Oncology (2014)
Abstract 15573: In-Hospital Switching of ADP Receptor Inhibitors in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the TRANSLATE-ACS Study
Authors: Akshay Bagai, Eric D Peterson, Emily Honeycutt, Mark B Effron, David J Cohen, Shaun G Goodman, Kevin Anstrom, Anjan Gupta, John C Messenger, Tracy Y Wang
Journal: Circulation (2012)

Background: While several ADP receptor inhibitors are now available, little is known regarding patterns of drug switching and associated patient selection factors. Methods: We studied ADP receptor ...
Outcomes of Stem Cell Transplantation with Fludarabine and Melphalan Conditioning for Children with Acquired Bone Marrow Failure: A Nationwide Retrospective Study
Authors: Nao Yoshida, Hiromasa Yabe, Kazuko Kudo, Ryoji Kobayashi, Miharu Yabe, Masami Inoue, Mizuka Miki, Hisashi Sakamaki, Koji Kato, Keisei Kawa, Ritsuro Suzuki, Ken-ichiro Watanabe, Seiji Kojima
Journal: Blood (2014)
Microsatellite Instability Phenotype of Tumors: Genotyping or Immunohistochemistry? The Jury Is Still Out
Authors: Albert de la Chapelle
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.4.897 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11844809 Microsatellite Instability Phenotype of Tumors: Genotyping or Immunohistochemistry? The Jury Is Still Out Albert de la ChapellexAlbert de la ChapelleSearch for articles by this author Show More Ohio State University, Columbus, OH https://doi.org/10.1200/JCO.2002.20.4.897 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Heparin use and venous thromboembolism (VTE) among cancer patients receiving chemotherapy with a prior history of VTE
Authors: G. Cherkowski, J. Dietrich, F. Chen, J. Fryzek, K. Bridges
Journal: Journal of Clinical Oncology (2009)

6616 Background: Heparin is an effective treatment option for the prevention of venous thromboembolism (VTE) in cancer patients on chemotherapy. To date, information on the use of both low molecular weight heparin (LMWH) and non-LMWH in cancer patients receiving chemotherapy that have had a prior VTE is lacking. We evaluated heparin treatment patterns as well as the incidence of VTE in a cohort of cancer patients receiving chemotherapy, who have had a VTE prior to their cancer diagnosis. Methods: We conducted a retrospective cohort study using a large claims database representing the U.S. commercially-insured population. The cohort included all patients 18–64 years old from 2000 to 2007 who were diagnosed with cancer, were on chemotherapy, and who had a VTE occurring up to 12 months before cancer (n=331). We defined a diagnosis of cancer as two ICD-9 claims 30 days apart or more. A combination of ICD-9, HCPCS, and CPT codes were used to capture chemotherapy treatment after cancer. A VTE was identified by a single ICD-9 claim of 415.1, 451.2, 451.81, 451.9, 453.1, 453.2, 453.8, or 453.9. VTE claims occurring within 6 months of the index claim were considered part of the same VTE event. A patient was considered to have a VTE after cancer if they had a VTE claim that occurred both after the cancer diagnosis and at least 6 months beyond the most recent pre-cancer index VTE date. Results: Fifty-one percent of cancer patients with a history of VTE were prescribed an anticoagulant (n = 171). Fewer patients took LMWH compared to non-LMWH (6.7% versus 27.8%) while a portion took both (17.2%). A VTE after cancer was experienced by 49.1% of those on any kind of anticoagulant, 45.4% of those taking LMWH, 43.5% of those taking non-LMWH, and 59.6% of those who had taken both types. Fewer VTEs were reported among those taking no anticoagulants (29.4%). Conclusions: Approximately half of all cancer patients receiving chemotherapy were receiving heparin, with a smaller proportion using only LMWH. Even with prophylaxis, VTE recurs in half of cancer patients with a VTE history who receive chemotherapy. Recurrent VTE is a serious risk despite heparin or LMWH prophylaxis. [Table: see text]
Evaluating a new income source for medical oncologists: Market research
Authors: K. R. Hoffman
Journal: Journal of Clinical Oncology (2007)

6629 Background: Recently market research has become a ‘booming business‘ serving pharmaceutical and biotechnology firms and financial institutions. From internet studies and focus groups to consultations with Wall Street analysts, medical oncologists are getting increasing involved in providing their expertise in non-patient matters. Payment is usually of a greater amount that what one would earn from direct patient care. Potentially, this may be the source of significant income. Methods: 47 private practice-based medical oncologists agreed to anonymously complete questionaires on this subject. 32 were returned (68% response rate). 17 academic hematologists and oncologists were approached. 7 returned completed questionaires (41% response rate). While group comparisons could not be made, some interesting points were found. Results: Each week an average of 6 Internet and 1 phone-based invitations week were received by the private practitioners. Most physicians received 2–3’ ‘focus group’ or ‘in-person’ invitations/month and attended the majority of them. Like in- person interviews, Internet-based marketing participation was based on the amount of money being offered and not on ‘interesting topic.‘ The majority of studies with an honorarium averaging $150/hour were completed. Academicians were much less likely to participate in Internet research. 4 of the 7 responded that they did not even open them. All participated in interviews, particularly if invited as a ‘key opinion leader‘ (KOL). With respect to interviews, the 3 major differences between the private practitioners and academicians were: in the number of requests received (1 vs 3/week); type and timing of interview requests (KOL received the majority of their interview requests from financial analyists and were inundated at or just around major oncology meetings); and the amount of reimbursement for an hour of interview time (Individual interviews for privates were in the $200–300 range. KOL interviews were reimbursed in the $500 to $5,000 range with $1,000–1,500 being the norm.) Conclusion: Clearly, market research is playing an increasing important role in the financial health of many physicians. Much more planned research needs to be done to see how this interaction affects individual physicians, patient care and society. No significant financial relationships to disclose.
Identification of potential diagnostic markers in bronchial fluid of patients with non small cell lung cancer (NSCLC)
Authors: G. Lopez-Vivanco, A. Muñoz, S. Carrera, R. Zalacain, M. Uribarri, J. Algorta, B. Calvo, U. Aresti, A. Buque, X. Mielgo
Journal: Journal of Clinical Oncology (2009)

e22216 Background: Early diagnosis in lung cancer could improve its treatment and, subsequently, its prognosis and survival. New proteomic techniques can identify potential diagnostic and prognostic markers. The aim of this study was to find protein markers in bronchial fluid which could enable early diagnosis in NSCLC. Methods: We have included 96 patients with NSCLC diagnosed using bronchoscope (64 scamous/29 adenocarcinoma/3 others) and 49 consecutive patients with non pathological bronchoscope. Bronchial fluid was obtained from each patient and potential protein markers were studied. Bronchial fluid was centrifuged and supernatant proteins were analysed using bidimensional electrophoresis with poliacrilamid gel stained with silver nitrate. Gel was scanned and analysed with Progenesis PG6220 program, which measures intensity of each spot. Resultant intensities in each group of patients (NSCLC/non pathological bronchoscope) were compared using T-Student method. We selected as potential markers those spots with a p value of less than 0.05. We calculated “fold change” of each spot as the ratio between mean intensity in NSCLC bronchoscopes samples and non pathological bronchoscopes samples. Results: We analysed 300 spots in each sample and we found 31 potential markers whose fold-change ranges from 1.49 to 7.41; 15 of the markers were expressed in a higher level in NSCLC samples and the other 16 were expressed in a lower level. Conclusions: We have identified 31 differential protein markers in bronchial fluid among our patients. These results could lead in an early diagnostic test which must be validated in future studies. No significant financial relationships to disclose.